Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section fda-regulatory-posture · Version 2026-09-13 · Cadence quarterly · Evidence class 1 registry · Sources 7 · Supersedes none
Domain: cross-cutting · Scope: Settles idea-002 REQ-0004 and REQ-0005 (knowledge-base/requests/ledger.csv). Neither the CPG text nor FD&C Act statutory text is codified in the CFR, so this repo's `regulation` connector (eCFR) cannot reach either directly — both were sought by WebSearch/WebFetch against FDA (US Food and Drug Administration)'s Compliance Policy Guides manual and Title 21 U.S. Code (law.cornell.edu). fda.gov is a named out-of-scope-blocked host in this repo (intermittent bot mitigation), and that bound this pass in practice: both current fda.gov URL paths for CPG Sec. 655.100 returned HTTP 401, and a Wayback Machine mirror was unreachable. No alternate host serving the CPG text was found. Two non-registry secondary pages (a veterinary association position statement, a law-firm blog post) were fetched and read but are not cited as numbered sources, because neither carries an identifier from this tree's closed vocabulary — see section 5. Excludes CPT (Current Procedural Terminology) descriptors, licensed veterinary datasets, PatentsView-gated material, and non-US/EU jurisdictions. Does not re-verify 21 CFR (Title 21 of the Code of Federal Regulations) 807.65(b)/807.20/807.81(a)/814.1(a), already checked via the `regulation` connector in knowledge-base/candidates/idea-002.md; re-retrieved here independently for this report's own citation trail.
Sourcing: Rests entirely on federal registry text retrieved directly this pass — 21 U.S.C. §§ 351/352 (Cornell Law's Legal Information Institute mirror) and five 21 CFR sections (7.3, 807.65, 807.20, 807.81, 814.1) via this repo's `regulation` connector. CPG 655.100 itself — the document both requests actually asked about — was not retrievable from any host reached this pass, and nothing about its wording is stated as a finding.
CPG Sec. 655.100's own text could not be retrieved this pass — fda.gov returned HTTP 401 on both current URL paths and no working mirror was found — so nothing about its wording is asserted below. Independent of the CPG, the CFR route this repo already used for idea-002 reaches the same premarket-exemption conclusion by a different mechanism: 21 CFR 807.65(b) exempts a manufacturer of devices used solely for veterinary purposes from § 807.20 registration, and the premarket notification duty at § 807.81(a) and the PMA (premarket approval) scope at § 814.1(a) each attach only to a device "intended for human use" [4][5][6][7]. On enforcement, 21 U.S.C. §§ 351/352 deem "a drug or device" adulterated or misbranded with no human-use qualifier in their opening clauses [2][3] — a direct textual contrast to the premarket provisions above — and FDA's own recall rule at 21 CFR 7.3(f) states the point affirmatively: "product" for recall purposes includes "any... device intended for human or animal use" [1]. Whether FDA actually exercises that authority against an animal-only device in practice could not be established; no device-specific enforcement action was located, and section 5 records two non-registry pages read on the question without treating either as a source of record.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
Both current fda.gov URL paths for "CPG Sec. 655.100 Devices for Use in Animals" returned HTTP 401. A Wayback Machine capture was located by timestamp (20260411013507) but could not be fetched — WebFetch refuses web.archive.org by design, and a direct request for that snapshot returned HTTP 403. No third host was found. No line below quotes the CPG.
21 U.S.C. § 351 opens: "A drug or device shall be deemed to be adulterated—" with its first ground being that the article "consists in whole or in part of any filthy, putrid, or decomposed" substance [2]. 21 U.S.C. § 352 opens: "A drug or device shall be deemed to be misbranded—" with its first ground being that "its labeling is false or misleading in any particular" [3]. Neither clause is restricted to human use, in contrast to 807.20(a)/807.81(a)/814.1(a) below, each of which is [5][6][7]. FDA's own recall regulation states the same point affirmatively rather than by omission: 21 CFR 7.3(f) defines "Product," for Part 7 recall/enforcement purposes, as "an article subject to the jurisdiction of the Food and Drug Administration, including any food, drug, and device intended for human or animal use" [1].
21 CFR 807.65(b) exempts "a manufacturer of devices to be used solely for veterinary purposes" from § 807.20 registration [4]. Section 807.20(a) limits that registration-and-listing duty to "a device intended for human use" [5]. Section 807.81(a) requires premarket notification only from a person required to register under § 807.20, for "a device intended for human use" [6]. Section 814.1(a) provides "procedures for the premarket approval of medical devices intended for human use" [7]. Combining these four into "no premarket duty for an animal-only device" is a synthesis this report makes, not a sentence any one section states — the same residue this repo's Verifier already recorded against idea-002's claim 1, flagged as an inference in section 5 rather than stated here as checked.
[1] 21 CFR 7.3 - Definitions (Part 7, Subpart C — Recalls) — eCFR, National Archives and Records Administration (issue 2026-09-10; accessed 2026-09-13). 21 CFR 7.3(f) — https://www.ecfr.gov/current/title-21/section-7.3 [federal-registry] [2] 21 U.S.C. § 351 - Adulterated drugs and devices — Legal Information Institute, Cornell Law School (Title 21 as currently in force; accessed 2026-09-13); cross-checked against 21 CFR 7.3(f)'s animal-use-inclusive product definition. 21 U.S.C. § 351; 21 CFR 7.3(f) — https://www.law.cornell.edu/uscode/text/21/351 [federal-registry] [3] 21 U.S.C. § 352 - Misbranded drugs and devices — Legal Information Institute, Cornell Law School (Title 21 as currently in force; accessed 2026-09-13); cross-checked against 21 CFR 7.3(f)'s animal-use-inclusive product definition. 21 U.S.C. § 352; 21 CFR 7.3(f) — https://www.law.cornell.edu/uscode/text/21/352 [federal-registry] [4] 21 CFR 807.65 - Exemptions for device establishments — eCFR, National Archives and Records Administration (issue 2026-09-10; accessed 2026-09-13). 21 CFR 807.65(b) — https://www.ecfr.gov/current/title-21/section-807.65 [federal-registry] [5] 21 CFR 807.20 - Who must register and submit a device list? — eCFR, National Archives and Records Administration (issue 2026-09-10; accessed 2026-09-13). 21 CFR 807.20(a) — https://www.ecfr.gov/current/title-21/section-807.20 [federal-registry] [6] 21 CFR 807.81 - When a premarket notification submission is required — eCFR, National Archives and Records Administration (issue 2026-09-10; accessed 2026-09-13). 21 CFR 807.81(a) — https://www.ecfr.gov/current/title-21/section-807.81 [federal-registry] [7] 21 CFR 814.1 - Scope — eCFR, National Archives and Records Administration (issue 2026-09-10; accessed 2026-09-13). 21 CFR 814.1(a) — https://www.ecfr.gov/current/title-21/section-814.1 [federal-registry]
Well established: Nothing rests on two independent, non-affiliated organizations — every source is either Cornell's Legal Information Institute or the federal government's own eCFR, so all of it stays single-source federal text rather than a plain multi-source statement.
Thin: All seven sources quote a statute's or regulation's own text, which needs no second witness to exist. What is thin is the synthesis across sources — combining 807.65(b)/807.20/807.81(a)/814.1(a) into "no premarket duty for an animal-only device" — which no single source states and which is marked as an inference below.
Rescoped from class 3: None. Both manifest questions ask what a named federal text states and whether a documented enforcement action exists; neither asks what a person would do.
Out of scope: CPT descriptors, licensed veterinary datasets, PatentsView-gated material, and non-US/EU jurisdictions.
Not searched vs. not found: CPG 655.100's own text — not found, not not-searched (two fda.gov paths fetched, both HTTP 401; one Wayback snapshot identified by timestamp, unfetchable). WebSearch results — never a source of record and not numbered above — consistently describe the CPG (issued June 1987, Center for Veterinary Medicine) as stating animal-use devices require no premarket clearance and may be deemed adulterated/misbranded under §§ 501/502 at CVM's determination; that is reported only as what search results say, not as a finding. A specific FDA enforcement action naming an animal-only device — not found: WebSearch queries for CVM warning/untitled letters and enforcement stories naming a device, not a drug, returned no matching primary record reachable by WebFetch. Two pages were fetched directly and read but excluded from section 4 for lacking a closed-vocabulary identifier: an AAEP position statement (dated 2026-03-30) states "Animal medical devices (including those marketed for equine) are not subject to FDA review for safety and effectiveness prior to coming to market," corroborating the premarket conclusion above by a different route, without naming the CPG or discussing enforcement; and an FDA Law Blog post (Hyman, Phelps & McNamara, published 2025-04-08) states "most Center for Veterinary Medicine (CVM) Warning Letters arise because products advertised are actually new animal drugs," with every worked example a drug, not a device — evidence about the shape of one firm's survey, not about whether FDA enforces against devices. A court opinion applying the CPG or §§ 501/502 to an animal-only device — not searched beyond one general query; no case-law database exists in this repo's tool surface.
[inference] Combining 21 CFR 807.65(b), 807.20(a), 807.81(a) and 814.1(a) into "no premarket notification or approval duty applies to a device labeled solely for animal use" is my synthesis across four sections, none of which states that combined proposition — the same residue this repo's Verifier already recorded against idea-002's claim 1. The contrast between §§ 351/352's unqualified "drug or device" language and §§ 807.20/807.81/814.1's "intended for human use" language is also mine; no single source states that contrast as a conclusion.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| 21 CFR 7.3(f) defines "Product" for FDA recall/enforcement purposes to include any device intended for human or animal use | 1 registry | 21 CFR 7.3(f) | reference-products |
| 21 U.S.C. § 351's adulteration provisions apply to "a drug or device" with no human-use qualifier in the introductory clause or its first listed ground | 1 registry | 21 U.S.C. § 351 | reference-products |
| 21 U.S.C. § 352's misbranding provisions apply to "a drug or device" with no human-use qualifier in the introductory clause, including the "false or misleading in any particular" ground | 1 registry | 21 U.S.C. § 352 | reference-products |
| 21 CFR 807.65(b) exempts a manufacturer of devices used solely for veterinary purposes from the § 807.20 registration requirement | 1 registry | 21 CFR 807.65(b) | reference-products |
| 21 CFR 807.81(a) requires premarket notification only from a person required to register under § 807.20 for a device intended for human use | 1 registry | 21 CFR 807.81(a) | reference-products |
| 21 CFR 814.1(a) scopes premarket approval procedures to medical devices intended for human use | 1 registry | 21 CFR 814.1(a) | reference-products |
_shared/plain-language.md